Your browser doesn't support javascript.
loading
Blood-brain barrier-crossing dendrimers for glioma theranostics.
Wang, Jinxia; Wang, Zhiqiang; Zhang, Guixiang; Rodrigues, João; Tomás, Helena; Shi, Xiangyang; Shen, Mingwu.
Afiliación
  • Wang J; State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai 201620, China. mwshen@dhu.edu.cn.
  • Wang Z; State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai 201620, China. mwshen@dhu.edu.cn.
  • Zhang G; Department of Radiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China. guixiangzhang@sina.com.
  • Rodrigues J; CQM-Centro de Quimica da Madeira, Universidade da Madeira, Funchal 9020-105, Portugal.
  • Tomás H; CQM-Centro de Quimica da Madeira, Universidade da Madeira, Funchal 9020-105, Portugal.
  • Shi X; State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai 201620, China. mwshen@dhu.edu.cn.
  • Shen M; CQM-Centro de Quimica da Madeira, Universidade da Madeira, Funchal 9020-105, Portugal.
Biomater Sci ; 12(6): 1346-1356, 2024 Mar 12.
Article en En | MEDLINE | ID: mdl-38362780
ABSTRACT
Glioma, as a disease of the central nervous system, is difficult to be treated due to the presence of the blood-brain barrier (BBB) that can severely hamper the efficacy of most therapeutic agents. Hence, drug delivery to glioma in an efficient, safe, and specifically targeted manner is the key to effective treatment of glioma. With the advances in nanotechnology, targeted drug delivery systems have been extensively explored to deliver chemotherapeutic agents, nucleic acids, and contrast agents. Among these nanocarriers, dendrimers have played a significant role since they possess highly branched structures, and are easy to be decorated, thus offering numerous binding sites for various drugs and ligands. Dendrimers can be designed to cross the BBB for glioma targeting, therapy or theranostics. In this review, we provide a concise overview of dendrimer-based carrier designs including dendrimer surface modification with hydroxyl termini, peptides, and transferrin etc. for glioma imaging diagnostics, chemotherapy, gene therapy, or imaging-guided therapy. Finally, the future perspectives of dendrimer-based glioma theraputics are also briefly discussed.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dendrímeros / Glioma Límite: Humans Idioma: En Revista: Biomater Sci Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dendrímeros / Glioma Límite: Humans Idioma: En Revista: Biomater Sci Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido